ad-fullscreen

Ruvo Center running drug trial aimed at delaying memory decline

Researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health are participating in a new clinical trial investigating whether treating older people with the drug solanezumab can delay memory decline in those who might be at risk to develop Alzheimer’s disease.

For the new clinical trial, doctors are looking for people in an asymptomatic stage of Alzheimer’s disease, said Dr. Charles Bernick, associate medical director of the Ruvo center. A certain amount of memory loss will not exclude a participant.

“All we require is that they score within a normal range of other people their age,” Bernick said. “They cannot have a diagnosis of Alzheimer’s disease or be taking any drugs for that. We’re looking for people who are functioning normally and don’t need any assistance.”

Positron emission tomography, known as PET scans, a test that shows how organs and tissues are working, will be used to determine whether participants have evidence of elevated buildup of amyloid, a protein found throughout the body. Participants should have normal thinking and memory function but evidence of elevated amyloid. Amyloid plaques can accumulate outside nerve cells and can lead to cell death in some people.

“We know that amyloid deposits begin years before you start really having symptoms,” Bernick said. “If you can use an agent that removes or prevents the buildup of amyloid, you actually might be able to prevent the disease.”

The overall goal of the study is to determine whether decreasing amyloid in the brain with antibody treatment can help slow the memory loss associated with amyloid buildup. The 3 ½-year Anti­-Amyloid Treatment in Asymptomatic Alzheimer’s study also aims to dis­cover more about brain markers and other tests to better predict who will experience memory decline and progress toward Alzheimer’s-related dementia.

Nationwide, some 1,150 healthy people age 65 to 85 are being recruited, and Bernick hopes to have 20-30 participants enrolled through the Ruvo center. Those selected to participate will be randomized to either receive solanezumab or a placebo once every four weeks by intravenous infusion.

Asymptomatic Alzheimer’s disease is a new concept being developed by physicians and researchers to describe when elevated amyloid buildup in the brain can be seen, but a person does not yet have any obvious clinical symptoms of Alzheimer’s disease.

Research studies suggest that older individuals with evidence of amyloid buildup might be at higher risk for memory loss, but that does not mean every person with elevated amyloid buildup will develop the clinical symptoms of Alzheimer’s disease.

Contact Steven Moore at smoore@reviewjournal.com or 702-380-4563.

section-ads_high_impact_4
TOP NEWS
ad-315×600
News Headlines
pos-2 — ads_infeed_1
post-4 — ads_infeed_2
Local Spotlight
Events
Home Front Page Footer Listing
Circular
You May Like

You May Like